A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Purpose

The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. The researchers will compare PK-targeted fludarabine dosing with standard fludarabine dosing to see which treatment approach is more effective. The researchers will also look at whether PK-targeted fludarabine dosing is feasible (practical), the side effects of the study treatment, and how the study treatment affects people's quality of life. The researchers will measure quality of life by having participants complete questionnaires.

Condition

  • B-cell Acute Lymphoblastic Leukemia

Eligibility

Eligible Ages
Over 1 Year
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with B-ALL and eligible to receive commercial tisagenlecleucel. - Patient's weight > 9 kg at time of lymphodepleting chemotherapy - Adequate organ function at time of LD is required and is defined: - Hepatic: Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia - Hepatic: AST and ALT < 5x the upper limit of normal for age, unless thought to be leukemic disease-related - Renal: Calculated glomerular filtration rate (GFR) ≥ 70 ml/min/1.73m^2. (based on Schwartz formula GFR (mL/min/1.73 m²) = (36.2 × Height in cm) / Creatinine in mg/dL - Cardiac: LVEF ≥ 50% by multi-gated acquisition scan (MUGA), resting echocardiogram, or cardiac magnetic resonance imaging (MRI) within 6 weeks of screening - Pulmonary: Oxygen saturation as recorded by pulse oximetry of ≥ 90% on room air - Adequate performance status: - Age ≥ 16 years: ECOG ≤ 1 or Karnofsky > 60% at treatment - Age < 16 years: Lansky ≥ 60% at treatment - Willing to participate as research subject and provide written informed consent from parents/legal representative, patient, and age-appropriate assent as appropriate before any study specific screening procedures are conducted, according to local, regional or national law and legislation.

Exclusion Criteria

  • Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to the study drugs, or drugs chemically related to study treatment or excipients that contraindicate their participation, including fludarabine, cyclophosphamide and tisagenlecleucel. - Patients with tisagenlecleucel that is deemed out of specification (OOS) will be excluded from this protocol - Clinically significant active and uncontrolled infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA etc.) - Patient/parent/guardian unable to give informed consent or unable to comply with the treatment protocol. - Pregnant or lactating women

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
The study is a randomized open-label multicenter trial.
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Standard Fludarabine regimen followed by CAR-T 		Fludarabine 30 mg/m2/dose x 4 doses on days -6 to -3 (or -7 to -4)
  • Drug: Fludarabine
    Fludarabine 30 mg/m2/dose x 4 doses on days -6 to -3 (or -7 to -4)
  • Drug: Cyclophosphamide
    All patients will receive Cyclophosphamide 500 mg/m2 IV on days -6 and -5 (or -7 and -6).
  • Biological: CAR-T
    will be infused based on institutional guidelines.
Experimental
Targeted fludarabine regimen followed by CAR-T 		Fludarabine 40 mg/m2/dose x 2 doses on days -6 and -5 (or -7 and -6), with doses on days -4 and -3 (or -5 and -4, if starting lymphodepletion on day -7) adjusted based on PK analysis to target a cumulative area under the curve (AUC) of 18 mg*h/L (range 17.5-18.5mg*h/L
  • Drug: Cyclophosphamide
    All patients will receive Cyclophosphamide 500 mg/m2 IV on days -6 and -5 (or -7 and -6).
  • Drug: Fludarabine
    Targeted fludarabine LD: Fludarabine 40 mg/m2/dose x 2 doses on days -6 and -5 (or -7 and -6), with doses on days -4 and -3 (or -5 and -4, if starting lymphodepletion on day -7) adjusted based on PK analysis to target a cumulative area under the curve (AUC) of 18 mg*h/L (range 17.5-18.5mg*h/L)
  • Biological: CAR-T
    will be infused based on institutional guidelines.

Recruiting Locations

Memorial Sloan Kettering Cancer Center
New York, New York 10065
Contact:
Kevin Curran, MD
1-833-MSK-KIDS

Cincinnati Children's Hospital Medical Center (Data Collection Only)
Cincinnati, Ohio 45229
Contact:
Christine Phillips, MD
513-636-4266

Children's Hospital of Philadelphia (Data Collection Only)
Philadelphia, Pennsylvania 19104
Contact:
Regina Myers, MD
267-426-0762

More Details

Status
Recruiting
Sponsor
Memorial Sloan Kettering Cancer Center

Study Contact

Kevin Curran, MD
1-833-MSK-KIDS
currank@mskcc.org